Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease

NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis

(2019) Stephen A. Harrison et al.   HEPATOLOGY

The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis

(2019) Patrick J. Antonellis et al.   Molecular Metabolism

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity

(2019) Zachary J. Ward et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial

(2018) Dana Friedrich et al.   BMC GASTROENTEROLOGY

NGM282 Significantly Reduces Hepatic Steatosis Independent of Type 2 Diabetes (T2D) Status or Statin Usage—Results from a Phase 2 Trial in Patients with Nonalcoholic Steatohepatitis (NASH)

(2018) ALEX DEPAOLI et al.   DIABETES

Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects

(2018) A. Ahmad et al.   JOURNAL OF HEPATOLOGY

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Stephen A Harrison et al.   LANCET

Association of serum fibroblast growth factor 19 levels with visceral fat accumulation is independent of glucose tolerance status

(2018) X. Hu et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics

(2018) Jiezhong Chen et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration

(2017) Gloria Alvarez-Sola et al.   GUT

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

(2017) Na Jiao et al.   GUT

Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15

(2017) Mei Zhou et al.   JOURNAL OF HEPATOLOGY

Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice

(2017) Bérengère Benoit et al.   NATURE MEDICINE

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Artificial local magnetic field inhomogeneity enhances T2 relaxivity

(2017) Zijian Zhou et al.   Nature Communications

Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease

(2016) Joel T. Haas et al.   Annual Review of Physiology

Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes

(2016) David P. Sonne et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease

(2016) Claudia Fuchs et al.   SEMINARS IN LIVER DISEASE

Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis

(2016) Natalia Gomez-Ospina et al.   Nature Communications

Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease

(2016) Marialena Mouzaki et al.   PLoS One

Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

(2015) Daniel Jahn et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease

(2014) Changtao Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Genetic Variation inNR1H4Encoding the Bile Acid Receptor FXR Determines Fasting Glucose and Free Fatty Acid Levels in Humans

(2013) Martin Heni et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway

(2013) Dongju Jung et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

(2013) Anna Alisi et al.   PLoS One

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

(2012) Fatih Eren et al.   CLINICAL BIOCHEMISTRY

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

(2012) M. J. Potthoff et al.   GENES & DEVELOPMENT

Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver

(2012) Claudia Cicione et al.   HEPATOLOGY

Dual actions of fibroblast growth factor 19 on lipid metabolism

(2012) Xinle Wu et al.   JOURNAL OF LIPID RESEARCH

Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism

(2012) Hongfei Ge et al.   PLoS One

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening

(2011) Eric T. Sawey et al.   CANCER CELL

FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway

(2011) Matthew J. Potthoff et al.   Cell Metabolism

FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

(2011) S. Kir et al.   SCIENCE

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance

(2010) Tim C. M. A. Schreuder et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse

(2010) Klementina Fon Tacer et al.   MOLECULAR ENDOCRINOLOGY

The Role of Peroxisome Proliferator-Activated Receptor γ Coactivator-1 β in the Pathogenesis of Fructose-Induced Insulin Resistance

(2009) Yoshio Nagai et al.   Cell Metabolism

Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis

(2009) Sushant Bhatnagar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice

(2009) X. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA